Business Wire

CA-MANSCAPED

13.4.2021 15:02:05 CEST | Business Wire | Press release

Share
Meet Paul Tran, Founder and CEO of Rocketship DTC Brand MANSCAPED™

Today, MANSCAPED™ , the global leader in men’s below-the-waist grooming, is cracking the code behind the company’s success with an exclusive introduction to its Founder and CEO, Paul Tran . From early beginnings to ongoing endeavors, Paul maintains a steadfast dedication to creativity, long-term thinking, and lifelong learning. These are just a few key takeaways as we get acquainted with the man leading MANSCAPED’s massive movement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005280/en/

A Born Entrepreneur. Born in Vietnam, Paul grew up with little, but with a big outlook on life. Although he experienced adversity at a young age, and as a first-generation immigrant in America who didn’t speak English, he reflects on his upbringing very fondly. Having nothing and coming from nothing ingrained a sense of ambition in Paul, driving him to make the most of any opportunity and practice empathy always.

After settling in New York, his vocabulary soon expanded beyond “hi” and, albeit the only Asian kid in school, he assimilated quickly among his peers and made friends due to his unassuming demeanor, self-awareness, and good nature. A born entrepreneur, Paul recalls one of his earliest memories from elementary school was when he hosted a raffle every Friday. It was a basic concept with no more than nickels on the table, but a weekly activity his classmates raved about and looked forward to. The popular game enhanced their lives unknowingly, while reaffirming Paul’s inner creative spirit.

Fast forward several years, this undeniable self-starter put himself through college at the University of Southern California where he studied at Marshall School of Business and Viterbi School of Engineering. He parlayed his education into his next ventures, which included launching and selling multiple businesses. One was a revolutionary science-backed skincare brand that provides a non-surgical solution for wrinkles and stretch marks. This was Paul’s first company that tackled taboos in the beauty space, but it most certainly wouldn’t be the last.

The MANSCAPED Movement. Paul launched MANSCAPED in 2016 with a vision of driving the movement that changes the face of men’s grooming. By focusing on the needs of what has, for too long, been a sensitive and often stigmatized subject, MANSCAPED has successfully untapped a vast market of male consumers. The brand not only provides premium tools and products for proper grooming but moves men forward by unlocking their confidence and allowing them to be the best versions of themselves. Paul lives by this mission every single day and envisions a world in the future where MANSCAPED plays a significant part in people’s lives all over the world.

Beyond seeing this vision materialize in real life, Paul thrives on working with his supportive and talented team. He is humble at his core, often highlighting teammates for execution and successes rather than taking any credit. This level of humility is understated but significant, as it flows deep into the organization. As CEO, Paul’s responsibilities are many. He loves overseeing the brand’s innovation and technology as a superior technician himself. He also spearheads the company’s direction as a brilliant strategist and constantly works to further establish MANSCAPED as an employer brand that puts company culture and people first. Ensuring that everyone feels valued, included, and appreciated for their efforts is extremely important to him.

Although at the helm of the entire MANSCAPED Family, Paul is a self-described introvert at heart and enjoys spending time in small groups where we can have meaningful conversations and directly care for his colleagues. His intelligent presentations, inspiring words, and witty humor are experienced by all 150 employees during MANSCAPED’s biweekly company-wide meetings. Calendar notifications go from mundane reminders to sparks of joy on these days. As a winner of Inc. Magazine ’s Best Workplaces in 2020, MANSCAPED is a workforce of individuals who are as happy as they are grateful for the environment Paul has created.

A Philanthropic Future. When he gets a sliver of time outside of MANSCAPED, Paul feeds his soul by spending time with his wife and two young children. This dedicated father and loving husband shares a special intellectual curiosity with his family. When their conversations run the gamut, Paul always walks away with a fresh perspective on life and appreciation for how far he has come. His deep-rooted desire to give back and commitment to social responsibility are fundamentals he has brought to MANSCAPED, as well as beliefs he lives by. Just one of his lifelong philanthropic goals is setting up his own foundation to help orphans and underprivileged children in Vietnam, which will be a full circle moment for him and so many others he’s impacted along the way.

About MANSCAPED™:

Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target and Best Buy locations throughout the U.S., with further domestic and international retailers coming soon. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye